Pediatric High Blood Pressure Management

Introduction to Management

The American Academy of Pediatrics recommends lifestyle modifications as the first line of treatment for all pediatric hypertension cases, with pharmacologic therapy reserved for specific high-risk situations, such as persistent hypertension despite lifestyle changes, symptomatic hypertension, Stage 2 hypertension without modifiable risk factors, or any stage of hypertension in patients with diabetes mellitus or chronic kidney disease (CKD) 1

The American Heart Association recommends a target blood pressure of <90th percentile for age or <130/80 mmHg (whichever is lower) for most pediatric patients ≥13 years old, based on evidence showing that hypertensive target organ damage (TOD) can appear at BP levels between the 90th and 95th percentiles, and that BP reduction below the 90th percentile can reverse left ventricular hypertrophy (LVH) 2

For children and adolescents with chronic kidney disease, the National Kidney Foundation recommends BP monitoring by ambulatory blood pressure monitoring (ABPM), with a goal 24-hour mean arterial pressure <50th percentile, based on the ESCAPE trial, which demonstrated slower CKD progression with this lower target compared to <90th percentile 2

The American Academy of Pediatrics specifies four clear indications for starting antihypertensive medications: persistent hypertension despite lifestyle modification, especially with an abnormal echocardiogram, symptomatic hypertension, Stage 2 hypertension without a modifiable risk factor, and any stage of hypertension in patients with diabetes mellitus or CKD 1

The American Heart Association recommends four drug classes as equally acceptable for initial therapy in pediatric patients with primary hypertension: ACE inhibitors, ARBs, long-acting calcium channel blockers, or thiazide diuretics, all of which have demonstrated pediatric efficacy and safety data 6
For hypertensive patients with CKD, diabetes mellitus, or proteinuria, the National Kidney Foundation strongly recommends ACE inhibitors or ARBs as the mandatory initial agent, due to their renal and cardiovascular protective effects in these populations 6

ACE inhibitors and ARBs are absolutely contraindicated in pregnancy and require reproductive counseling before initiation in females of childbearing potential due to teratogenic effects 7

The American Academy of Pediatrics recommends starting at the low end of the dosing range and titrating every 2-4 weeks until blood pressure normalizes 7

The American Heart Association recommends implementing the DASH diet with saturated fat restricted to 7% of total calories and dietary cholesterol to 200 mg/day, as well as eliminating added salt and reducing high-sodium foods 7
The American Academy of Pediatrics recommends prescribing moderate to vigorous physical activity at least 3-5 days per week for 30-60 minutes per session, and counseling weight loss of at least 5% of body weight if the patient is overweight 7

The American Academy of Pediatrics recommends echocardiography to assess for left ventricular hypertrophy, particularly before initiating pharmacologic treatment, and defines LVH as LV mass >51 g/m²·⁷ for children and adolescents >8 years of age, or alternatively as LV mass >115 g/body surface area for boys and >95 g/body surface area for girls 5

The American Academy of Pediatrics recommends seeing patients every 4-6 weeks until blood pressure normalizes, and then extending follow-up visits to every 3-4 months after BP control is achieved 7

The American Heart Association recommends monitoring for ACE inhibitor/ARB-specific adverse effects, including cough, hyperkalemia, and renal function changes, as well as monitoring electrolytes with thiazide diuretics 7